We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $3B
1-Year Est. Return 46.72%
This Fund
S&P 500
This Quarter Est. Return
+0.18%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.03B
AUM Growth
+$47.9M
Cap. Flow
-$1.25B
Cap. Flow %
-41.28%
Top 10 Hldgs %
36.47%
Holding
100
New
13
Increased
18
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$79.8M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$37.4M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$34M
4
HROW icon
Harrow
HROW
+$24.8M
5
IMCR icon
Immunocore
IMCR
+$24M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$30.7M
2
TVTX icon
Travere Therapeutics
TVTX
+$30.6M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$25.7M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
51
Adaptive Biotechnologies
ADPT
$3.56B
$5.73M 0.19%
+648,451
New +$5.72M
ALXO icon
52
ALX Oncology
ALXO
$273M
$5.65M 0.19%
1,249,900
+991,620
+384% +$7.51M
SILK
53
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$2.48M 0.08%
63,331
-353,486
-85% -$17.3M
IMTX icon
54
Immatics
IMTX
$1.24B
$2.22M 0.07%
322,287
-927,765
-74% -$7.59M
ESPR
55
DELISTED
Esperion Therapeutics
ESPR
$1.93M 0.06%
1,211,519
-2,181,886
-64% -$11.3M
REPL icon
56
Replimune Group
REPL
$814M
$1.3M 0.04%
73,665
-588,684
-89% -$14M
AVTX icon
57
Avalo Therapeutics
AVTX
$976M
$433K 0.01%
+1,030
New +$811K
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$4.25B
– –
-1,493,121
Closed -$23.8M
ALLK
59
DELISTED
Allakos
ALLK
– –
-920,304
Closed -$7.75M
APLS
60
DELISTED
Apellis Pharmaceuticals
APLS
– –
-389,596
Closed -$20.1M
COO icon
61
Cooper Companies
COO
$13.7B
– –
-208,460
Closed -$17.2M
EW icon
62
Edwards Lifesciences
EW
$47.6B
– –
-235,319
Closed -$17.6M
ITOS
63
DELISTED
iTeos Therapeutics
ITOS
– –
-71,585
Closed -$1.4M
KOD icon
64
Kodiak Sciences
KOD
$2.59B
– –
-914,209
Closed -$6.55M
MIST icon
65
Milestone Pharmaceuticals
MIST
$144M
– –
-1,164,849
Closed -$4.61M
MLTX icon
66
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-381,120
Closed -$4M
NKTR icon
67
Nektar Therapeutics
NKTR
$2.39B
– –
-41,352
Closed -$1.4M
NKTX icon
68
Nkarta
NKTX
$162M
– –
-1,525,800
Closed -$9.14M
PTGX icon
69
Protagonist Therapeutics
PTGX
$8.75B
– –
-927,800
Closed -$10.1M
QDEL icon
70
QuidelOrtho
QDEL
$1.09B
– –
-300,437
Closed -$25.7M
RAPT
71
DELISTED
RAPT Therapeutics
RAPT
– –
-125,000
Closed -$19.8M
SRPT icon
72
Sarepta Therapeutics
SRPT
$1.66B
– –
-140,352
Closed -$18.2M
TVTX icon
73
Travere Therapeutics
TVTX
$5.33B
– –
-1,455,585
Closed -$30.6M
VRDN icon
74
Viridian Therapeutics
VRDN
$2.13B
– –
-313,403
Closed -$9.15M
FUSN
75
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-2,000,000
Closed -$6.3M
1 2
3
4

Similar funds

NC
NZS Capital Denver, Colorado $3B AUM 21.29% 1-Year Est. Return
SGI
Swan Global Investments Durango, Colorado $3B AUM 15.66% 1-Year Est. Return
SP
SurgoCap Partners New York $2.99B AUM 39.34% 1-Year Est. Return
DIG
Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3B AUM 24.41% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Braidwell's Q1 2023 Portfolio in Review

As of Q1 2023, Braidwell held 100 positions worth $3.03B, up 1.6% from $2.98B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Braidwell withdrew a net $1.25B in Q1 2023, closing 19 positions and reducing 21 holdings. Its most notable exit was Travere Therapeutics, an estimated $30.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 57% a quarter earlier.

Against the trend, Braidwell opened a new position in Neurocrine Biosciences worth $77.6M.

  • Braidwell's largest Q1 2023 buy was Neurocrine Biosciences: 766,800 shares worth $77.6M.
  • Braidwell added most to Day One Biopharmaceuticals in Q1 2023, an estimated $37.4M increase.
  • Braidwell's biggest Q1 2023 reduction was Natera, cutting an estimated $30.7M.
  • Braidwell fully exited Travere Therapeutics in Q1 2023, selling an estimated $30.6M.
  • Braidwell's ten largest holdings make up 36% of its $3.03B portfolio in Q1 2023.
  • Braidwell opened 13 new positions and closed 19 in Q1 2023.
  • Braidwell's portfolio value rose 1.6% quarter-over-quarter to $3.03B.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.